Zacks Investment Research on MSN4d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback